Provided by Tiger Trade Technology Pte. Ltd.

Orchestra BioMed

5.06
+0.01500.30%
Volume:30.51K
Turnover:155.27K
Market Cap:302.70M
PE:-5.06
High:5.35
Open:5.02
Low:4.95
Close:5.04
52wk High:5.78
52wk Low:2.20
Shares:59.88M
Float Shares:33.00M
Volume Ratio:1.20
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9995
EPS(LYR):-1.1091
ROE:-397.30%
ROA:-45.73%
PB:15.67
PE(LYR):-4.56

Loading ...

Orchestra BioMed Joins Russell 3000® and Russell 2000® Indexes

GlobeNewswire
·
Jun 29

Orchestra BioMed Shareholders Approve Directors and Incentive Plan

TIPRANKS
·
Jun 24

Orchestra BioMed shareholders approved 2026 annual meeting proposals

Reuters
·
Jun 24

Orchestra BioMed Holdings (OBIO) Gets a Hold from BTIG

TIPRANKS
·
Jun 18

Orchestra BioMed posts investor deck spotlighting pivotal-stage AVIM hypertension therapy and Virtue sirolimus balloon program

Reuters
·
Jun 04

Orchestra BioMed CEO, Chair David P. Hochman acquires 5,000 common shares worth $19,150

Reuters
·
Jun 03

Orchestra BioMed COO Darren Sherman disposes of 15,000 common shares worth $58,050

Reuters
·
Jun 03

Orchestra BioMed grants options for 85,500 shares to five new hires under inducement plan

Reuters
·
Jun 03

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 03

Top Brass Double Down on Orchestra BioMed as Insider Buying Heats Up

TIPRANKS
·
May 20

Orchestra BioMed Holdings Is Maintained at Buy by B. Riley Securities

Dow Jones
·
May 20

Orchestra BioMed CEO joins Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 19

Orchestra BioMed CEO, Chair David Hochman buys 5,000 shares for $18,850

Reuters
·
May 19

Orchestra BioMed director Aryeh Jason buys 8,971 shares valued at $34,986.9

Reuters
·
May 19

B. Riley Cuts Price Target on Orchestra BioMed Holdings to $10 From $12, Keeps Buy Rating

MT Newswires Live
·
May 19

Orchestra BioMed director Eric S. Fain acquires 20,000 shares worth $82,600

Reuters
·
May 18

Orchestra BioMed releases corporate presentation on pivotal-stage AVIM hypertension and Virtue SAB programs

Reuters
·
May 14

Orchestra BioMed Holdings Is Maintained at Overweight by Barclays

Dow Jones
·
May 13

Orchestra BioMed price target raised to $13 from $12 at Barclays

TIPRANKS
·
May 13

Orchestra BioMed reports Q1 EPS (33c), consensus (44c)

TIPRANKS
·
May 13